1. Risk Factors Associated with Adverse Events Leading to Methotrexate Withdrawal in Elderly Rheumatoid Arthritis Patients: A Retrospective Cohort Study.
- Author
-
Avalos-Salgado, Felipe Alexis, Gonzalez-Lopez, Laura, Gonzalez-Vazquez, Sergio, Ponce-Guarneros, Juan Manuel, Santiago-Garcia, Aline Priscilla, Amaya-Cabrera, Edna Lizeth, Arellano-Cervantes, Reynaldo, Gutiérrez-Aceves, J. Ahuixotl, Alcaraz-Lopez, Miriam Fabiola, Nava-Valdivia, Cesar Arturo, Gonzalez-Ponce, Fabiola, Rodriguez-Jimenez, Norma Alejandra, Macias-Islas, Miguel Angel, Valdivia-Tangarife, Edgar Ricardo, Saldaña-Cruz, Ana Miriam, Cardona-Muñoz, Ernesto German, and Gamez-Nava, Jorge Ivan
- Subjects
RHEUMATOID arthritis ,COHORT analysis ,OLDER patients ,OLDER people ,METHOTREXATE - Abstract
Background: Rheumatoid arthritis (RA) in elderly population represents a challenge for physicians in terms of therapeutic management. Methotrexate (MTX) is the first-line treatment among conventional synthetic-disease-modifying anti-rheumatic drugs (cs-DMARDs); however, it is often associated with adverse events (AEs). Therefore, the objective of this study was to identify the incidence and risk factors of MTX discontinuation due to AEs in elderly patients with RA in a long-term retrospective cohort study. Methods: Clinical sheets from elderly RA patients taking MTX from an outpatient rheumatology consult in a university centre were reviewed. To assess MTX persistence, we used Kaplan–Meir curves and Cox regression models to identify the risk of withdrawing MTX due to adverse events. Results: In total, 198 elderly RA patients who reported using MTX were included. Of them, the rates of definitive suspension of MTX due to AEs were 23.0% at 5 years, 35.6% at 10 years and 51.7% at 15 years. The main organs and system involved were gastrointestinal (15.7%) and mucocutaneous (3.0%). Factors associated with withdrawing MTX due to AEs were MTX dose ≥ 15 mg/wk (adjusted HR: 2.46, 95% CI: 1.22–4.96, p = 0.012); instead, the folic acid supplementation was protective for withdrawal (adjusted HR: 0.28, 95% CI: 0.16–0.49, p < 0.001). Conclusions: Higher doses of MTX increase the risk of withdrawals in elderly RA, while folic acid supplementation reduces the risk. Therefore, physicians working in therapeutic management for elderly patients using MTX must focus on using lower MTX doses together with the concomitant prescription of folic acid. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF